ArticleFrontiers in oncology2025
Methylation detection in percutaneous lung biopsy preservation fluid: a new strategy to improve lung cancer diagnosis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Value of RASSF1A and SHOX2 methylation detection in intraoperative pleural lavage fluid for potential microdissemination and prognosis evaluation in non-small cell lung cancer.World journal of surgical oncology · 2026Article
- Using gene methylation detection in bronchoscopic samples combined with morphology-based pathology for lung cancer diagnosis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lung cancer is a significant global health threat, particularly in China, where it has high incidence and mortality rates. Current diagnostic methods face challenges, especially in obtaining sufficient tissue samples for accurate diagnosis. This study aimed to develop a new strategy using percutaneous lung biopsy preservation fluid for gene methylation detection to improve diagnostic accuracy. Methods: A total of 182 patients who underwent percutaneous lung biopsy were included in the study. The preservation fluid was replaced with a formalin-free solution for sample collection. DNA was extracted from these samples for methylation detection of SHOX2 and RASSF1A genes. Results: The results showed that the DNA concentration qualification rate of the preservation fluid was 98.4%, and the internal reference Ct value qualification rate was 97.6%. New cut-off values were established (▵Ct Discussion: In conclusion, methylation detection in percutaneous lung biopsy preservation fluid, when combined with traditional pathology, can effectively reduce missed diagnoses and is worthy of further promotion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.